GLP-1 Receptor Agonists for Type 2 Diabetes: Incorporating the Latest Treatment Options Into Individualized Care (Webinar 2)

Explore Type 2 Diabetes Case Studies and Join the Live Q&A Period in This Free Webinar
Type 2 Diabetes Webinar Info

December 17, 2020 3:00pm – 4:15pm (ET) Online

CE: 1.25 contact hours (CH) of continuing education (CE)
1.25 of which may be applied toward pharmacology.

This live webinar, presented by the American Association of Nurse Practitioners® (AANP), is your second opportunity to gain an update on diabetes care, including how to overcome clinical inertia utilizing the 2020 American Diabetes Association (ADA) treatment algorithm. Expert nurse practitioner (NP) faculty will present three case studies to illustrate how to set individualized therapeutic goals for the rapid attainment of HbA1c targets, intensify medication therapy utilizing the ADA’s 2020 guidelines and identify patients for whom a GLP-1 receptor agonist may reduce cardio- and cerebrovascular events. Please note: This webinar contains the same content as the first webinar in this activity series, which took place on October 30. Learners should only complete one offering of this activity to earn CE credit. A recorded version of this webinar is now available in the AANP CE Center!

Event Details
  • Webinar Details

    GLP-1 Receptor Agonists for Type 2 Diabetes: Incorporating the Latest Treatment Options Into Individualized Care

    When: December 17, 2020, 3–4:15 p.m. ET (2–3:15 p.m. CT).

    Where: Online via the AANP CE Center.

    Cost: Free.

    CE credit: This educational activity is pending approval by AANP of up to 1.25 CH of accredited CE, which includes 1.25 pharmacology.

    View in the AANP CE Center


    About the Webinar

    Diabetes effects more than 31 million people in the U.S., 91% of whom have Type 2 diabetes (T2D). Despite understanding the health benefits of intensive glycemic control — including decreased risk of myocardial infarction, heart failure and stroke — only 52% patients have their glycated hemoglobin (HbA1c) at or below 7%.

    In this CE program, speakers Dixie Harms and Shannon Idzik, both NPs with expertise in diabetes care, discuss how to overcome clinical inertia utilizing the 2020 ADA treatment algorithm. Three case studies will be presented to help NPs in clinical practice understand how and when to incorporate GLP-1 receptor agonists into practice, set individualized therapeutic goals, achieve rapid attainment of HbA1c targets and help patients maintain glycemic control. This 1.25-CH CE program, which includes 1.25 pharmacology credit, will be hosted on three occasions as a webinar with a live faculty question-and-answer (Q&A) period directly following each session. A clinical resource tool will be available to learners who complete the activity. In addition, a recorded version of this webinar will be available on demand in the AANP CE Center until January 18, 2021, and a synopsis of the Q&A will be available once the program is launched in the AANP CE Center.

    This live webinar is made available for AANP members and nonmember NPs at no cost, thanks to an independent medical education grant from NovoNordisk.

    Please note: This webinar contains the same content as the first webinar in this activity series, GLP-1 Receptor Agonists for Type 2 Diabetes: Incorporating the Latest Treatment Options Into Individualized Care, which took place on October 30. Learners should only complete one offering of this activity to earn CE credit. Completing multiple offerings for the same activity is considered duplicate credit for the same content and may not be accepted by some regulatory bodies.


    Webinar Objectives

    • Describe the short- and long-term adverse outcomes of elevated HbA1c levels.
    • Appraise the importance of the regular assessment of HbA1c levels and the modification of treatment for patients who are not meeting goals.
    • Diagram treatment plans for the rapid attainment of HbA1c targets.
    • Prioritize factors associated with a patient-centered approach for T2D management, including cardiovascular comorbidities, risk for hypoglycemia and patient preferences.
    • Explain individualized and evidence-based strategies to overcome barriers to T2D pharmacotherapy adherence.

    View in the AANP CE Center

  • Speakers

    Webinar Faculty

    Shannon Idzik, DNP, ANP-BC, FAANP, FAAN

    Dr. Idzik is an associate professor and associate dean of the Doctor of Nursing Practice program at University of Maryland School of Nursing. She has been on faculty there since 2005 and previously served as the program director for the Adult Gerontology NP program. She has worked clinically as an NP in endocrinology, bariatric surgery and primary care, where she managed large panels of patients with diabetes. She currently maintains a faculty practice as an NP in the University of Maryland Comprehensive Care Center, where she also manages patients with diabetes. She was awarded the AANP State Award for Excellence in 2012, was selected as a Fellow of the American Association of Nurse Practitioners (FAANP) in 2014 and a Fellow of the American Academy of Nursing (FAAN) in 2017. Dr. Idzik is a reviewer for numerous peer-reviewed journals and speaks regularly on diabetes around the nation.

    Dixie L. Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP

    Dr. Harms has been a family nurse practitioner (FNP) at MercyOne Clinics in Des Moines since 2002, working in family practice, internal medicine and endocrinology specialty practice areas. Most recently, she works in both the Comfort Health Center for Women and Family Medicine clinics. Dr. Harms received her doctorate of nursing practice (DNP) from University of Iowa College of Nursing in 2009, Post-Master’s FNP Certificate from Clarkson College (1997), Master of Science in Nursing (1993) and Bachelor of Science in Nursing (1986) from Drake University and Diploma of Nursing from Iowa Methodist School of Nursing (1985) in Des Moines, Iowa.

    Dr. Harms has been a member of AANP since 1996, where she has served as a State Representative, Regional Director and on the AANP Board of Directors, and she has planned and spoken at several national conferences. Dr. Harms has served on the Journal of the American Association of Nurse Practitioners (JAANP) Editorial Board and assisted in the development and presentation of multiple CE programs.

    She was inducted into the FAANP in 2005 and has served as Secretary and Chair of the Nominations Committee. She has also been involved with the American Academy of Nurse Practitioners Certification Board (AANPCB) since 1999. She has been a Commissioner since 2016 and has served as Treasurer, served on the Nominations Committee and has participated in test construction, item writing and test bank maintenance. In her spare time, Dr. Harms enjoys gardening, golf and photography.